Actively Recruiting
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-22
56
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.
CONDITIONS
Official Title
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 2 18 years old
- Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria:
- Definite limbic autoimmune encephalitis according to 2016 Graus et al. criteria
- Possible autoimmune encephalitis according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF
- Probable or certain paraneoplastic neurological syndrome according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes)
- Less than 6 months since first neurological symptoms attributable to autoimmune encephalitis
- Affiliated or entitled to a social security system (except AME)
- Provided free, written, and informed consent (patient or legal representative or close relative)
You will not qualify if you...
- History of brain tumor, head trauma, infarction, or cerebral hematoma likely to alter cerebral carbohydrate metabolism on PET
- Immunotherapy treatment for more than 10 days (including corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab, or other immunotherapies)
- Pregnant or breastfeeding women
- Ventilated intubated patients
- Absolute contraindication to MRI (e.g., pacemaker, cochlear implant)
- Cognitive disorders incompatible with good cooperation during the PET scan
- Painful or agitated patients unable to remain immobile in supine position for 30 minutes
- Individuals deprived of liberty or under protective measures (guardianship or curatorship)
- Participation in other interventional research involving radiopharmaceutical injections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Pitie Salpetriere
Paris, France, 75013
Actively Recruiting
Research Team
A
Aurélie Kas, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here